Biotech IPOs are cautiously returning, but Big Pharma's aggressive M&A for pipeline replenishment creates intense market competition.
Read More
The Geo Chronicle
Your Window to World Affairs
Biotech M&A Surge Signals Strongest Market Recovery Since 2019
Biotech M&A is booming in 2026, driven by patent cliffs and market recovery, signaling the strongest dealmaking since 2019.
Read More
Abivax Shares Plunge as Clinical Trial Data Raises Cancer Concerns
Abivax shares dropped significantly after new clinical trial data for its ulcerative colitis drug revealed cancer concerns, impacting its future.
Read MoreYOU MAY HAVE MISSED
